Clinical Trial Update: Renal and Systemic Effects of NCX4016 in Patients With Type 2 Diabetes and Early Nephropathy [Phase 2]

View source ↗

Summary

A Phase 2 study of NCX4016 in patients with Type 2 diabetes and early nephropathy was terminated. No efficacy or safety results are provided in the update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy
• Type 2 Diabetes Mellitus

Drugs mentioned

• NCX4016 (NCX4016)

Snippet

Sponsor: Mario Negri Institute for Pharmacological Research | Conditions: Type 2 Diabetes, Early Nephropathy | Phase 2 | Status: TERMINATED